Due to the popularity of the research and development of “covid-19 self-test product”, the share price of Andon Health Co.Ltd(002432) which has risen more than 10 times in two months has been interviewed recently.
It is reported that Andon Health Co.Ltd(002432) previously disclosed only some successful experimental results, but not all experimental results, and the disclosure information is incomplete.
important experimental information
has been interviewed
The chairman and Secretary of Andon Health Co.Ltd(002432) were interviewed because only some experimental results of covid-19 self-test products were disclosed.
On the evening of February 14, Andon Health Co.Ltd(002432) disclosed that the company received the decision on administrative regulatory measures (hereinafter referred to as the decision) and the decision on taking regulatory conversation measures against Liu Yi and Wu Tong issued by Tianjin regulatory bureau of China Securities Regulatory Commission.
In January this year, Andon Health Co.Ltd(002432) received the experimental report on the test performance of ihealth covid-19 antigen home self-test OTC kit against Omicron variant virus from the Radx project of the National Institutes of Health (NIH) arranged by the U.S. Food and Drug Administration (FDA). Then Andon Health Co.Ltd(002432) announced and disclosed the above matters. The announcement said, The report shows that ” ihealth-covid-19 antigen rapid test detected 100% of Omicron active virus samples with a maximum CT value of 21.59 (n = 5) “.
The reason why Tianjin Securities Regulatory Bureau decided to take regulatory talk measures on Andon Health Co.Ltd(002432) is that the company only disclosed some successful experimental results, did not disclose all experimental results , and the disclosure information is incomplete.
Previously, Andon Health Co.Ltd(002432) mentioned in the reply to the attention letter of Shenzhen stock exchange that in the disclosed results, “maximum” means that samples less than or equal to 21.59 can be 100% detected, and samples greater than 21.59 cannot be 100% detected, He also said that “the positive detection rate of all samples in the experimental group: can be detected when the CT value is ≤ 21.59, 60% can be detected when the CT value is 22.86, and can not be detected when the CT value is ≥ 23.87″. Therefore, Andon Health Co.Ltd(002432) only discloses some experimental results.
Tianjin Securities Regulatory Bureau said that Liu Yi, as the chairman and general manager of Andon Health Co.Ltd(002432) , and Wu Tong, as the Secretary of Andon Health Co.Ltd(002432) board of directors, bear the main responsibility for the integrity of information disclosure in the interim report of listed companies. Tianjin Securities Regulatory Bureau decided to take supervision and management measures for the two people.
In response to the receipt of the decision, Wu Tong told the Beijing business daily, “the regulatory authorities pointed out that there are deficiencies in the integrity of the letter Phi on this announcement. It is normal for the company to talk and guide. The company understands, respects and accepts the opinions of the regulatory authorities and will improve it in the future work, but we don’t have to break it down”.
According to China first finance, today, Andon Health Co.Ltd(002432) said it had made a complete disclosure of information in accordance with regulatory requirements.
authorized in the United States
The share price of soared more than 10 times in two months
Covid-19 self-test product of Andon Health Co.Ltd(002432) was authorized by FDA in November last year. Once the news was released, its share price rose more than 10 times in the next two months.
This is not the first time that Andon Health Co.Ltd(002432) has attracted regulatory attention. Since November 16 last year, Shenzhen Stock Exchange has issued three attention letters and one supervision letter to Andon Health Co.Ltd(002432) . The company has also issued announcements of abnormal fluctuations in stock trading and stock trading risk warning for many times, and the product causing stock price fluctuations and supervision is the covid-19 self-test product of Andon Health Co.Ltd(002432) .
In November 2021, Andon Health Co.Ltd(002432) announced that it was authorized by the U.S. Food and Drug Administration (FDA) to establish ihealth labs Inc, a U.S. subsidiary of the company. The New Coronavirus (SARS-CoV-2) antigen self testing OTC Kit (gelled immunochromatography) is used for emergency use authorization (EUA), which can be sold in the US during the public health emergency and in the United States and the EUA countries.
of Andon Health Co.Ltd(002432) This product can be used for rapid and qualitative detection of covid-19 virus in human anterior nasal swab samples in vitro. Individuals can collect covid-19 virus by themselves and quickly produce results in 15 minutes. The detection process is faster and more efficient.
When Andon Health Co.Ltd(002432) at that time, it is expected to bring relevant sales revenue to the company in the future.
Once the above news was released, Andon Health Co.Ltd(002432) share price soared and gained multiple trading boards. Or under the continuous influence of the above news, Andon Health Co.Ltd(002432) share price rose more than 10 times in the next two months.
The announcement that the letter Phi was deemed incomplete by Tianjin Securities Regulatory Bureau also made Andon Health Co.Ltd(002432) ‘s share price fluctuate. The share price of Andon Health Co.Ltd(002432) rose 6.05% on the day of disclosing the performance test report of home self-test OTC kit against Omicron mutant virus.
” the experimental report involved a lot of professional contents. At that time, the company mainly considered that there were many professional terms involved and did not want to write the announcement too difficult to interpret, so it used a relatively concise statement , stated the test results of the company’s kit products on Omicron virus, and also wrote the original translation and original link of the suggestions and conclusions given by FDA based on this situation in the announcement. The announcement of the company also considered that investors can understand the relevant situation through the company’s official information to avoid misinformation, Mainly based on the perspective of investor protection. ” Wu Tong said.
Wang Chikun, an independent economist and financial commentator, said that due to the impact of the epidemic, testing enterprises have become the darling of the capital market. Under the capital overweight, the concept stocks are hot. However, with the effective control of the epidemic, there will also be a correction process for the hot sector pursued by capital.
popular epidemic prevention concept
expected profit of more than 900 million yuan
Covid-19 self-test products have attracted market and regulatory attention, and also brought performance returns to Andon Health Co.Ltd(002432) .
As a listed enterprise focusing on the R & D and production of health electronic products and intelligent hardware, Andon Health Co.Ltd(002432) was established in 1995. After landing on the Shenzhen Stock Exchange in 2010, Andon Health Co.Ltd(002432) became the first listed enterprise in China’s sphygmomanometer industry, and its products cover the fields of blood pressure, blood glucose, blood oxygen and so on. However, 2013-2019, Andon Health Co.Ltd(002432) has been negative net profit deduction, long-term performance under pressure .
However, with the hot sales of epidemic prevention products such as forehead temperature gun, Andon Health Co.Ltd(002432) 2020 performance increased significantly. Recently, Andon Health Co.Ltd(002432) disclosed its 2021 performance forecast. The sales of self testing OTC kit products benefited from New Coronavirus (SARS-CoV-2) increased significantly in the US market. The company expects to profit 900 million -12 billion yuan , up by 271.4%-395.19% compared with the same period last year.
Cao Bo, a medical consultant of biotech innovative drugs, believes that according to the Andon Health Co.Ltd(002432) stock trading risk warning announcement, the historical performance of kit products does not represent future performance, and the uncertainty of epidemic development, market competition and contracts / orders are all risks
